PRETORIA, South Africa--(BUSINESS WIRE)--Synexus has further expanded its global presence with the opening of a new in-patient facility in Pretoria, South Africa. Synexus now has a total of four sites in South Africa which provides access to millions of patients. The Nyeleti research facility (‘Nyeleti’ meaning ‘STAR’ in Sotho) has been developed for Phase II and III studies which involve 24 hour serial spirometry (lung function), mixed meal tolerance testing, PK (what happens to a drug in the body) visits requiring an overnight stay or when infusion is required. This new site will support the existing Synexus clinical trial centres in Pretoria and Mamelodi.
This modern facility includes an in-patient ward as well as a secure, temperature controlled dispensing unit designed to manage supplies according to ICH GCP and national guidelines. It also houses emergency and other resuscitative equipment, a transit laboratory and food preparation area and has ambulance support.
Dr Christophe Berthoux CEO of Synexus said: “Synexus recognises the vital role South Africa has to play in global clinical trials and continues to invest in the region. In addition to providing access to a large patient pool, many of whom are treatment naive, the medical infrastructure and training is of a very high standard. There is also a high public awareness of the benefits of clinical trials which speeds up recruitment and overcomes the lengthy regulatory process. These are all key factors in ensuring the success of a clinical trial.”
Dr Sanet Aspinall, Managing Director of Synexus South Africa, who is responsible for the management of the South African sites, commented: “We are well positioned to continue our success as the leading professional investigator organisation in South Africa that meets, and often exceeds, our clients’ needs in conducting phase 2-4 studies. Access to a core group of well trained and experienced staff at our new in-patient unit and at our dedicated research centres, fast recruitment through our innovative recruitment strategies and the delivery of high quality data will enable us to meet our goals for future growth as a global player in the clinical research industry.
- ENDS -